We are live on ! Find out more
CA

CHI Advisors Portfolio holdings

AUM $252M
1-Year Est. Return 56.99%
This Fund
S&P 500
This Quarter Est. Return
+31.84%
1 Year Est. Return
+56.99%
3 Year Est. Return
+88.23%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$375M
AUM Growth
+$3.55M
Cap. Flow
-$50.9M
Cap. Flow %
-13.55%
Top 10 Hldgs %
91.86%
Holding
26
New
1
Increased
9
Reduced
6
Closed
3
Avg Time Held Equity + Options
7.9 quarters
Top 10 Avg Time Held Equity + Options
4.5 quarters
Top 20 Avg Time Held Equity + Options
6.8 quarters
Avg Time Held Equity only
8.3 quarters
Top 10 Avg Time Held Equity only
4.5 quarters
Top 20 Avg Time Held Equity only
6.8 quarters

Top Buys

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$11.1M
2
RLYB icon
Rallybio
RLYB
+$3.92M
3
IMA icon
ImageneBio Inc
IMA
+$1.13M
4
KZR icon
Kezar Life Sciences
KZR
+$939K
5
CGEM icon
Cullinan Oncology
CGEM
+$903K

Top Sells

Rank Stock Value
1
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$44M
2
AKUS
Akouos Inc
AKUS
+$8.71M
3
PLRX icon
Pliant Therapeutics
PLRX
+$5.01M
4
RPTX icon
Repare Therapeutics
RPTX
+$4.03M
5
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$3.43M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Miscellaneous 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
RXDX
1
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$102M 27.06%
923,800
-677,985
-42% -$44M
2021 Q1
7 quarters
PLRX icon
2
Pliant Therapeutics
PLRX
$61.6M
$61.3M 16.32%
3,169,892
-239,866
-7% -$5.01M
2020 Q2
10 quarters
VECT
3
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
$47.6M 12.68%
5,492,893
+1,373,321
+33% +$11.1M
2021 Q2
6 quarters
RPTX icon
4
DELISTED
Repare Therapeutics
RPTX
$41.2M 10.97%
2,800,126
-269,721
-9% -$4.03M
2020 Q2
10 quarters
CGEM icon
5
Cullinan Oncology
CGEM
$961M
$35M 9.32%
3,317,544
+74,359
+2% +$903K
2021 Q1
7 quarters
LRMR icon
6
Larimar Therapeutics
LRMR
$267M
$14.3M 3.82%
3,473,366
+58,218
+2% +$199K
2020 Q2
10 quarters
CMPX icon
7
Compass Therapeutics
CMPX
$167M
$14.2M 3.79%
2,829,712
– –
2021 Q4
4 quarters
KZR icon
8
DELISTED
Kezar Life Sciences
KZR
$13.3M 3.54%
188,945
+12,666
+7% +$939K
2019 Q3
13 quarters
KROS icon
9
Keros Therapeutics
KROS
$231M
$10.3M 2.75%
215,059
+14,830
+7% +$693K
2020 Q2
10 quarters
OMGA icon
10
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
$6.03M 1.61%
1,055,882
– –
2021 Q3
5 quarters
RLYB icon
11
Rallybio
RLYB
$89.9M
$4.77M 1.27%
90,764
+66,477
+274% +$3.92M
2022 Q3
1 quarter
IMA icon
12
ImageneBio Inc
IMA
$48.2M
$4.36M 1.16%
136,448
+35,256
+35% +$1.13M
2021 Q1
7 quarters
DTIL icon
13
Precision BioSciences
DTIL
$179M
$4.22M 1.13%
118,327
-4,167
-3% -$165K
2019 Q3
13 quarters
TSVT icon
14
DELISTED
2seventy bio
TSVT
$3.12M 0.83%
333,252
-196,971
-37% -$2.78M
2022 Q1
3 quarters
ORTX
15
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$2.96M 0.79%
798,740
– –
2019 Q3
13 quarters
INZY icon
16
DELISTED
Inozyme Pharma
INZY
$2.32M 0.62%
2,204,876
+208,599
+10% +$365K
2020 Q3
9 quarters
FRLN
17
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$2.29M 0.61%
320,961
– –
2020 Q3
9 quarters
CRVS icon
18
Corvus Pharmaceuticals
CRVS
$845M
$2.03M 0.54%
2,384,402
– –
2019 Q3
13 quarters
GTHX icon
19
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$1.81M 0.48%
333,945
+10,000
+3% +$83.8K
2020 Q2
10 quarters
OVID icon
20
Ovid Therapeutics
OVID
$473M
$1.61M 0.43%
864,822
– –
2019 Q3
13 quarters
ONCR
21
DELISTED
Oncorus, Inc.
ONCR
$600K 0.16%
2,367,436
– –
2020 Q4
8 quarters
LABD icon
22
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$134M
$431K 0.11%
2,500
-2,500
-50% -$512K
2022 Q3
1 quarter
PLRX icon
23
CALL
Pliant Therapeutics
PLRX
$61.6M
$29.3K 0.01%
+30,000
New +$627K
2022 Q4
0 quarters
NKTX icon
24
Nkarta
NKTX
$157M
– –
-117,599
Closed -$1.55M –
EIGR
25
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-15,170
Closed -$3.43M –
1
2

Similar funds

SC
Samjo Capital New York $254M AUM 36.81% 1-Year Est. Return
T
TRUADVICE Sarasota, Florida $255M AUM 14.45% 1-Year Est. Return
W
WealthOne Albany, New York $248M AUM 17.79% 1-Year Est. Return
RBGI
Ribbit Bullfrog GP II Palo Alto, California $258M AUM 33.43% 1-Year Est. Return
TOGEPT
Trustees of General Electric Pension Trust Norwalk, Connecticut $245M AUM 128.88% 1-Year Est. Return
IAM
Innovis Asset Management Chicago, Illinois $260M AUM 28.13% 1-Year Est. Return
RCGI
Ribbit Capital GP II Palo Alto, California $260M AUM 2.87% 1-Year Est. Return
AEPLI
AH Equity Partners LSV III Menlo Park, California $262M AUM 59.24% 1-Year Est. Return

CHI Advisors's Q4 2022 Portfolio in Review

As of Q4 2022, CHI Advisors held 26 positions worth $375M, up 0.96% from $372M the previous quarter. Its ten largest holdings account for 92% of the portfolio.

CHI Advisors withdrew a net $50.9M in Q4 2022, closing 3 positions and reducing 6 holdings. Its most notable exit was Akouos Inc, an estimated $8.71M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, CHI Advisors added an estimated $11.1M to VectivBio Holding AG Ordinary Shares.

  • CHI Advisors added most to VectivBio Holding AG Ordinary Shares in Q4 2022, an estimated $11.1M increase.
  • CHI Advisors's biggest Q4 2022 reduction was Prometheus Biosciences, Inc. Common Stock, cutting an estimated $44M.
  • CHI Advisors fully exited Akouos Inc in Q4 2022, selling an estimated $8.71M.
  • CHI Advisors's ten largest holdings make up 92% of its $375M portfolio in Q4 2022.
  • CHI Advisors opened 1 new position and closed 3 in Q4 2022.
  • CHI Advisors's portfolio value rose 0.96% quarter-over-quarter to $375M.

Based on CHI Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.